Laurel Wealth Advisors LLC Sells 140 Shares of DexCom, Inc. (NASDAQ:DXCM)

Laurel Wealth Advisors LLC reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 16.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 728 shares of the medical device company’s stock after selling 140 shares during the quarter. Laurel Wealth Advisors LLC’s holdings in DexCom were worth $90,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of DXCM. Cary Street Partners Investment Advisory LLC increased its stake in DexCom by 11.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock valued at $108,000 after acquiring an additional 115 shares during the last quarter. CX Institutional bought a new position in shares of DexCom during the 4th quarter valued at about $286,000. abrdn plc raised its holdings in shares of DexCom by 21.1% during the 4th quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock valued at $47,221,000 after buying an additional 66,348 shares in the last quarter. Cerity Partners LLC boosted its stake in DexCom by 5,791.0% in the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock worth $57,574,000 after buying an additional 456,097 shares in the last quarter. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in shares of DexCom during the fourth quarter worth approximately $57,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 1.2 %

Shares of DXCM traded up $1.47 during mid-day trading on Monday, reaching $125.81. The company had a trading volume of 3,845,948 shares, compared to its average volume of 3,056,784. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The company has a market capitalization of $50.03 billion, a price-to-earnings ratio of 81.17, a price-to-earnings-growth ratio of 2.11 and a beta of 1.20. The firm has a 50-day moving average price of $131.30 and a 200 day moving average price of $119.17.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. On average, sell-side analysts forecast that DexCom, Inc. will post 1.78 EPS for the current year.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the transaction, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the transaction, the chief executive officer now directly owns 333,526 shares in the company, valued at approximately $44,479,027.36. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Sadie Stern sold 20,321 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the transaction, the executive vice president now directly owns 80,441 shares in the company, valued at approximately $10,747,722.01. The disclosure for this sale can be found here. In the last ninety days, insiders sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several analyst reports. Raymond James upped their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday. UBS Group lifted their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Citigroup increased their price objective on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Canaccord Genuity Group lifted their target price on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Royal Bank of Canada initiated coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $141.67.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.